DALLAS, TX – (NewMediaWire) – December 30, 2021 – NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused, commercially operational RAS (Recirculating Aquaculture System), today announced the funding of a second freshwater salmon trial at the Marineholmen RASLab, in Bergen, Norway.
In September 2021, the Company announced initial trial results of its short-term validation study at the Marineholmen RASLab to evaluate the effects of using Hydrogas technology to increase fish health in a Recirculating Aquaculture System (RAS). The positive results from that trial led to the initiation of a second phase trial during the first quarter of 2022 that will include not only Hydrogas technology, but also the Company’s patented electrocoagulation (EC) technology. If successful, the second phase trial would provide independent scientifically validated confirmation of the use of these technologies to improve salmon production.
Christine Huynh, DVM aquatic species consultant for NaturalShrimp, added, “In this study we will investigate the effects of hydrogas on fish welfare and performance in freshwater salmon production. The study will include smoltification and transfer into saltwater. We are also including some additional analyses on the microbiome to understand if the negative ORP environment influences the consortium of bacteria in RAS.”
“Our initial validation study results demonstrated that fish grown using Hydrogas technology had significantly improved welfare scores, fewer inflammatory gill lesions and reduced early maturation,” said Gerald Easterling, CEO of NaturalShrimp. “With these promising early results, we are now focused on proving that Hydrogas and our EC technology together can reduce mortality and increase growth rates for our existing shrimp production. These platform technologies could be significant breakthroughs for NaturalShrimp because they will enable us to obtain a separate revenue stream through the licensing of these technologies to aquaculture producers of salmon, barramundi, and other freshwater fish. We look forward to sharing results later in the coming year as we continue to scale production of our land-based gourmet-grade shrimp.”
NaturalShrimp, Inc. is a publicly traded aquaculture company, headquartered in Dallas, with production facilities located near San Antonio, Texas and Webster City, Iowa. The Company has developed the first commercially viable system for growing shrimp in enclosed, salt-water systems, using patented technology to produce fresh, never frozen, naturally grown shrimp, without the use of antibiotics or toxic chemicals. NaturalShrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp. For more information visit www.naturalshrimp.com.
This press release contains includes a number of forward-looking statements that reflect management’s current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements include statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2021, any of which may cause our company’s or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements.
Investor Relations Contact
Executive Vice President
MZ North America
The post NaturalShrimp Announces Second Phase Trial for Freshwater Salmon first appeared on Smallcaps Daily.